Stockscreener 앱 받기
0.618
2.49%
0.015
시간 외 거래:
.62
0.002
+0.32%
Veru Inc 주식(VERU)의 최신 뉴스
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024 - mx.advfn.com
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter - mx.advfn.com
Is Veru Inc (NASDAQ: VERU) A Great Stock To Invest In? - Stocksregister
Cetera Investment Advisers Boosts Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - MSN
Veru Inc. (NASDAQ:VERU) Shares Sold by Northern Trust Corp - Defense World
Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leave - Seeking Alpha
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study By Investing.com - Investing.com South Africa
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says - BioPharma Dive
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study - Investing.com Australia
Veru Reports Positive Safety Results From Phase 2B Quality Study - marketscreener.com
Veru Reports Positive Safety Results from Phase 2b QUALITY Study - GuruFocus
Veru (VERU) Advances Enobosarm in Clinical Trials with Promising - GuruFocus
Veru’s enobosarm shows increased fat loss, muscle preservation and safety - TipRanks
Veru, GameStop, Azul - TradingView
Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide - Nasdaq
Veru Reports Positive Safety Results from Phase 2b QUALITY - GlobeNewswire
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - Yahoo Finance
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha
B. Riley Forecasts Veru's Q4 Earnings (NASDAQ:VERU) - MarketBeat
B. Riley Analysts Decrease Earnings Estimates for Veru - Defense World
MPM Bioimpact LLC Acquires New Shares in Veru Inc. (NASDAQ:VERU) - MarketBeat
Veru Target of Unusually Large Options Trading (NASDAQ:VERU) - Defense World
Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial - MSN
Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Barclays PLC Acquires 21,738 Shares of Veru Inc. (NASDAQ:VERU) - Defense World
Veru Inc. (NASDAQ:VERU) Stake Raised by Wells Fargo & Company MN - Defense World
Veru Inc. (NASDAQ:VERU) Q2 2025 Earnings Call Transcript - Insider Monkey
Veru Inc. Reports Progress in Clinical Trials and Financials - TipRanks
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... - Yahoo Finance
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... By GuruFocus - Investing.com Canada
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
Earnings call transcript: Veru Inc. beats Q2 2025 EPS forecast, stock rises - Investing.com India
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Veru Q2 2025 Earnings Call Transcript - MarketBeat
Veru Inc. (VERU) Advances Obesity Program with Promising Trial Results - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
Veru Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Veru Participates in a Virtual Investor KOL Connect Segment | VERU Stock News - GuruFocus
JTC Team Hosts Virtual Investor “KOL Connect” Segment to Discuss Veru Inc.’s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level - Sacramento Bee
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level - Weatherford Democrat
Veru Participates in a Virtual Investor KOL Connect Segment - GlobeNewswire
2 Beaten-Down Stocks That Are Great Buys on the Dip - The Globe and Mail
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025 - marketscreener.com
Veru Inc (VERU) Reports Q2 Fiscal 2025 EPS of -$0.05, Beating Estimates of -$0.06; Revenue Focus Remains on Clinical Progress - GuruFocus
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress | VERU Stock News - GuruFocus
1.21%
1.51%
자본화:
|
볼륨(24시간):